Biologics — Pipeline, Approvals, Sponsors

Therapeutic proteins, recombinant proteins, peptides, and monoclonal antibodies. The dominant innovative-drug class by sales — Humira, Keytruda, Dupixent are all biologics.

1,672
Marketed
0
Filed
1,482
Phase 3
1,427
Phase 2
2,807
Phase 1
7,455
Total

Marketed leaders

Recent approvals (last 30 days)

No approvals in the last 30 days.

Upcoming PDUFA (next 180 days)

No upcoming PDUFA in next 180 days.

Top sponsors in this modality

  1. GlaxoSmithKline · 465 biologics
  2. Sanofi Pasteur, a Sanofi Company · 177 biologics
  3. Merck Sharp & Dohme LLC · 169 biologics
  4. · 155 biologics
  5. Pfizer · 136 biologics
  6. Assistance Publique - Hôpitaux de Paris · 105 biologics
  7. ModernaTX, Inc. · 92 biologics
  8. National Institute of Allergy and Infectious Diseases (NIAID) · 65 biologics
  9. Sinovac Biotech Co., Ltd · 64 biologics
  10. Sanofi · 62 biologics

Drug classes within Biologics

Subscribe to ongoing alerts

Push every new biologics event into your RSS reader:

Other modalities

Monoclonal AntibodiesSmall MoleculesAntibody-Drug ConjugatesCell TherapiesGene TherapiesGene EditingmRNA TherapeuticssiRNA TherapeuticsAntisense OligonucleotidesBispecific AntibodiesVaccines

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing